We are live on ! Find out more

MESO

Mesoblast

MESO

Market cap $1.95B

15.02 USD

-0.46

2.97%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

15.02

0.00

0%

1 day

-2.97%

5 days

-10.11%

1 month

-3.72%

3 months

9.16%

6 months

2.67%

Year to date

-17.29%

1 year

-2.85%

5 years

18.08%

10 years

66.89%

About: Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Employees: 108

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 30.8%

Neutral 61.5%

Negative 7.7%

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript

Mesoblast Reports Substantial Revenue Growth to US$120M

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very pleased to report a strong full year gross profit of US$104M for the fiscal year 2026.

Mesoblast Reports Substantial Revenue Growth to US$120M

Mesoblast H2 Earnings Call Highlights

Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.

Mesoblast H2 Earnings Call Highlights

Zacks Investment Research

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast Limited (NASDAQ:MESO) stock is trading higher on Monday after the company concluded patient dosing for its crucial Phase 3 clinical trial evaluating rexlemestrocel-L.

Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-discal injection of rexlemestrocel-L or sham injection. Total patient numbers treated increased from 300 to 350 after strong demand from trial investigators to have their patients enrolled in the innovative program.

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain Activity Report for Quarter Ended June 30, 2026 (Appendix 4C) NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the fourth fiscal quarter ended June 30, 2026. “We are very pleased with the continued momentum in uptake of Ryoncil® in children with life-threatening steroid-refractory acute GvHD across major U.S. pediatric centers, positioning the treatment well for use next in adults with this life-threatening disease.

Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Zacks Investment Research

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis

Mesoblast transitions to a commercial-stage company, anchored by FDA-approved Ryoncil and robust early revenue growth. Ryoncil's regulatory, reimbursement, and manufacturing precedents de-risk MESO's broader mesenchymal lineage platform and future label expansions. Cash burn has decreased, non-dilutive funding strengthens the balance sheet, and pipeline progress supports a platform premium valuation.

Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis

See News Rankings

Price charts implemented using Lightweight Charts™